Abiraterone acetate: a review in metastatic castration-resistant prostate cancer

Compliance with Ethical Standards

Funding: The preparation of this review was not supported by any external funding.

Conflict of interest: Lesley Scott is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information about this Adis Drug Review can be found at here.

Abstract

Oral abiraterone acetate (Zytiga®) is a selective inhibitor of CYP17 and thereby inhibits androgen biosynthesis, with androgen signalling crucial in the progression from primary to metastatic prostate cancer (PC) and subsequently, in the development of metastatic castration-resistant PC (mCRPC). In large phase 3 trials and in the clinical practice setting, oral abiraterone acetate in combination with prednisone was an effective treatment and had an acceptable, manageable tolerability and safety profile in chemotherapy-naive and docetaxel-experienced men with mCRPC, with an. In the pivotal global phase 3 trials, relative to placebo plus prednisone, abiraterone acetate plus prednisone prolonged overall survival (OS) at data maturity (final analysis) and prolonged radiographic progression-free survival (rPFS) at all assessed timepoints. Given its efficacy in prolonging OS and its convenient once-daily oral regimen, in combination with prednisone, abiraterone acetate is an important first-line option for the treatment of mCRPC. Access to the full article can be found here.

© Springer International Publishing AG, part of Springer Nature 2017